PMV Pharmaceuticals, Inc.
PMVP Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.27
KIRA · Stoqly’s AI analyst, in plain words
- PMV Pharmaceuticals, Inc. had $6.3M of revenue in fiscal 2025, down 40.5% on the year before. Over five years, revenue changed +57.6% a year on average.
- Its operating margin was −1,360.4%, down 558.4 pts: of every 100 in sales, about −1,360 is left after running the business.
- PMV Pharmaceuticals, Inc. lost $77.7M in fiscal 2025.
- Free cash flow was −$73.6M in fiscal 2025, −1,161.5% of revenue.
Market cap
$67.8M
P/E
—
Revenue
$6.3M
Net income
−$77.7M
Free cash flow
−$73.6M
Operating margin
−1,360.4%
PMV Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−40.5%
No. Sales fell 40.5% last year.
Does it make a profit?
−1,226.8%
No. It lost money last year.
Does profit turn into cash?
−1,161.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What PMV Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 6, 2026
- Legal name
- PMV Pharmaceuticals, Inc.
- CIK
- 0001699382
PMV Pharmaceuticals, Inc. · PMVP
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.4M | $3.6M | $11.2M | $10.7M | $6.3M |
| Revenue growth | −31.0% | 707.8% | 208.0% | −4.6% | −40.5% |
| Net interest income | $0.4M | $3.6M | $11.2M | $10.7M | $6.3M |
| Operating margin | −12,982.9% | −2,124.1% | −717.3% | −802.0% | −1,360.4% |
| Net income | −$57.8M | −$73.3M | −$69.0M | −$58.7M | −$77.7M |
| Net margin | −12,883.3% | −2,021.4% | −617.3% | −551.0% | −1,226.8% |
| Diluted EPS | −$1.28 | −$1.61 | −$1.44 | −$1.14 | −$1.48 |
| Cash | |||||
| Cash from operations | −$46.6M | −$63.8M | −$55.7M | −$51.3M | −$73.6M |
| Capital expenditure | $1.3M | $8.0M | $1.0M | $0.7M | $0.0M |
| Free cash flow | −$47.9M | −$71.7M | −$56.6M | −$51.9M | −$73.6M |
| FCF margin | −10,672.6% | −1,978.1% | −506.8% | −487.4% | −1,161.5% |
| Share count change | 214.2% | 1.0% | 5.3% | 7.4% | 1.9% |
| Debt and strength | |||||
| Cash and short-term investments | $297M | $241M | $203M | $169M | $113M |
| Shareholders' equity | $309M | $246M | $226M | $176M | $105M |
| Current ratio | 24.7x | 22.8x | 14.8x | 12.2x | 10.1x |
| Returns and quality | |||||
| Return on equity | −17.3% | −26.4% | −29.2% | −29.2% | −55.4% |
| Return on tangible equity | −18.7% | −29.8% | −30.6% | −33.3% | −74.2% |
| Piotroski F-score | 1 | 2 | 2 | 2 | 1 |
| Altman Z'' | 17.0 | 11.5 | 7.8 | 8.4 | −2.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
PMV Pharmaceuticals, Inc. · PMVP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.27 a share, the company is worth $67.8M.
Source: SEC EDGAR XBRL filings (CIK 0001699382). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.